Key result
Managing mechanical heart valves during pregnancy requires balancing the teratogenic risks of coumadin against the maternal risks of valve failure associated with heparin alternatives.
Why the study?
Does the choice of anticoagulation strategy balance maternal safety and fetal outcomes in pregnant women with mechanical heart valves?
Does the choice of anticoagulation strategy balance maternal safety and fetal outcomes in pregnant women with mechanical heart valves?
This review highlights the complex trade-offs between fetal teratogenicity with warfarin and maternal valve failure with heparins in pregnant women with mechanical heart valves.
Answers are grounded in this paper and cite their sources.
Balancing anticoagulation risks remains essential for pregnant women with mechanical valves; leaves open optimal regimens without randomized data.
Mechanical heart valves pose a particular challenge in pregnancy, as the primary agent used to prevent valve thrombosis, coumadin (warfarin), is a known teratogen. Alternatives to coumadin, such as unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) are safer for the fetus, particularly during the first trimester of pregnancy, but expose the mother to potential valve failure. This review will examine these controversies and the complex literature regarding management in pregnancy.
No takes yet. Share an insight, caveat, or question.
Maxwell et al. (2007) conducted a review in Mechanical heart valves in pregnancy. Anticoagulation (coumadin, UFH, LMWH) was evaluated. Managing mechanical heart valves during pregnancy requires balancing the teratogenic risks of coumadin against the maternal risks of valve failure associated with heparin alternatives.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: